Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isavuconazonium - Basilea Pharmaceutica

Drug Profile

Isavuconazonium - Basilea Pharmaceutica

Alternative Names: AK-1820; ASP-9766; BAL-8557; BAL-8557-000; BAL-8557-002; BAL-9557; Cresemba; isavuconasole; Isavuconazole - Basilea Pharmaceutica; Isavuconazonium chloride; Isavuconazonium sulfate; Isavuconazonium sulphate

Latest Information Update: 07 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Asahi Kasei Pharma Corp; Astellas Pharma; Avir Pharma; Basilea Pharmaceutica; Grupo Biotoscana; Hikma Pharmaceuticals; Pfizer
  • Class Antifungals; Antineoplastics; Nitriles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive bronchopulmonary aspergillosis; Candidiasis; Candidaemia; Zygomycosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Invasive bronchopulmonary aspergillosis; Zygomycosis
  • Phase III Candidiasis; Mycoses
  • Phase I Haematological malignancies

Most Recent Events

  • 29 Oct 2019 Registered for Invasive bronchopulmonary aspergillosis in Brazil (IV)
  • 29 Oct 2019 Registered for Invasive bronchopulmonary aspergillosis in Brazil (PO)
  • 29 Oct 2019 Registered for Zygomycosis in Brazil (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top